One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Japan Nuclear Imaging Market

[ 英語タイトル ] Japan Nuclear Imaging Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0083833
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 80
Category : Healthcare and Pharmaceuticals
Study Area : Japan
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3250 / Question Form
5 User USD3750 / Question Form
Enterprise User USD6500 / Question Form
 - ATOX CO. Ltd
- Bracco Imaging SpA
- CANON INC.
- Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
- GE HEALTHCARE
- IBA Radiopharma Solutions
- JFE Engineering Corporation
- Koninklijke Philips NV
- Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
- Siemens Healthineers

[Report Description]

Japan Nuclear Imaging market is expected to witness a CAGR of 6.85% during the forecast period. Certain factors that are driving the market growth include the rise in prevalence of cancer and cardiac disorders, increase in technological advancements, growth in the applications of nuclear medicine and imaging.

After being ranked the topmost cause of life-loss in the last century, stroke is now the third-ranked cause of death in Japan, following cancer and heart disease. According to the 2018 article, “Lifestyle and cardiovascular disease in Japan”, the recent trend of rising CHD (coronary heart disease) prevalence among the urban population is a cause for serious concern, as a potential source of forthcoming problems for public health as well as clinical practice in Japan. Moreover, due to the association between lifestyle and CVD (cardiovascular disease), higher sodium, lower calcium, and lower animal protein content in the diet, along with higher alcohol consumption, may account for the higher prevalence of hypertension and higher risk of stroke in the Japanese population than for western population at same BMI levels. According to the latest OECD data, in Japan, patients with end-stage kidney failure (ESKF), often caused by diabetes and hypertension, are the highest in the OECD at 238 per 100,000 population while the average is 101. Thus, the increasing prevalence of cancer, along with certain cardiovascular diseases, is expected to propel the growth of the nuclear imaging market in Japan.

Key Market Trends

Single Photon Emission Computed Tomography Equipment is Expected to Hold a Significant Market Share

As per the scope of the report, SPECT equipment includes planar scintigraphy, stand-alone SPECT, hybrid SPECT/CT equipment along with radioisotopes delivery systems, etc. SPECT significantly differs from other types of radiologic and tomographic imaging modalities, such as CT scan or conventional radiography. In SPECT, rather than passing x-rays through a patient to form an image, the patient is injected with a radiopharmaceutical which then emits radiation in the form of gamma rays or x-rays, which are detected by a gamma camera. Advances in image processing algorithms, innovations in radionuclide and ligands, and the advent of multi-modality imaging systems are driving the market growth for modern SPECT and SPECT/CT devices.

Competitive Landscape

The Japan Nuclear Imaging market is moderately competitive and consists of a few major players. Companies like ATOX CO. Ltd, Bracco Imaging SpA, CANON INC., Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), GE HEALTHCARE, IBA Radiopharma Solutions, JFE Engineering Corporation, Koninklijke Philips NV, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), Siemens Healthineers, among others, hold the substantial market share in the Japan Nuclear Imaging market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
4.2.2 Increase in Technological Advancements
4.2.3 Growth in the Applications of Nuclear Medicine and Imaging
4.3 Market Restraints
4.3.1 High Cost of Techniques
4.3.2 Short Half-life of Radiopharmaceuticals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Product
5.1.1 Equipment
5.1.2 Radioisotope
5.1.2.1 SPECT Radioisotopes
5.1.2.1.1 Technetium-99m (TC-99m)
5.1.2.1.2 Thallium-201 (TI-201)
5.1.2.1.3 Gallium (Ga-67)
5.1.2.1.4 Iodine (I-123)
5.1.2.1.5 Other SPECT Radioisotopes
5.1.2.2 PET Radioisotopes
5.1.2.2.1 Fluorine-18 (F-18)
5.1.2.2.2 Rubidium-82 (RB-82)
5.1.2.2.3 Other PET Radioisotopes
5.2 Application
5.2.1 SPECT Applications
5.2.1.1 Orthopedics
5.2.1.2 Thyroid
5.2.1.3 Cardiology
5.2.1.4 Other SPECT Applications
5.2.2 PET Applications
5.2.2.1 Oncology
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.4 Other PET Applications

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ATOX CO. Ltd
6.1.2 Bracco Imaging SpA
6.1.3 CANON INC.
6.1.4 Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
6.1.5 GE HEALTHCARE
6.1.6 IBA Radiopharma Solutions
6.1.7 JFE Engineering Corporation
6.1.8 Koninklijke Philips NV
6.1.9 Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
6.1.10 Siemens Healthineers

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+